Please login to the form below

Not currently logged in
Email:
Password:

Merck KGaA appoints biosimilar head

Simon Sturge joins from Boehringer Ingelheim
Simon Sturge, Merck KGaA

Simon Sturge is to leave his role at Boehringer Ingelheim to join fellow German healthcare company Merck KGaA as head of its new biosimilars unit.

From March 1, Sturge will run the company's biosimilars division, which was set up in 2012 to develop copies of biological treatments with a focus on oncology and inflammatory disorders. 

Based in Canton de Vaud, Switzerland, the unit will include both in-house and partnership-based development to create biosimilars, which are seen as a major growth area over the next few years as patents for biological medicines expire.

Sturge is currently head of biopharmaceuticals at Boehringer, where his responsibilities include biosimilars.

His prior experience in pharma includes several CEO positions, such as Vernalis, Lonza Biologics and Celltech Biologics.

With his appointment, Sturge succeeds Thierry Hulot, who created Merck KGaA's biosimilars unit but later took over responsibility for global manufacturing and supply for its pharma unit Merck Serono.

21st February 2014

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics